Conatus Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Conatus Pharmaceuticals, Inc. - overview
Established
2005
Location
San Diego, CA, US
Primary Industry
Pharmaceuticals
About
Conatus Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for liver diseases by targeting cell death pathways to improve patient outcomes. Founded in 2005 and headquartered in San Diego, US, Conatus Pharmaceuticals specializes in innovative treatments for liver conditions. The company has undergone strategic pivots and raised USD 66 mn in its IPO on July 25, 2013, offering 6 million shares at USD 11 per share.
The company has completed 8 deals throughout its operational history. Conatus Pharmaceuticals is engaged in the development of novel therapies aimed at treating liver diseases, with a focus on enhancing liver health through its unique approaches to targeting cellular mechanisms involved in liver damage. In the most recent fiscal year of 2019, Conatus Pharmaceuticals reported a revenue of USD 21. 72 mn, alongside an EBITDA of USD -12.
14 mn. With the recent IPO funding of USD 66 mn targeted for future development, Conatus Pharmaceuticals is set to expand its therapeutic offerings and research initiatives. The company is focused on launching new products aimed at liver disease management and exploring collaborations to enter new markets by 2025.
Current Investors
Aberdare Ventures, Gilde Healthcare, Advent Venture Partners
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.conatuspharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.